MétaCan
Menu
Back to cohort

BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

2016· article· en· W2486369884 on OpenAlexaff
Denis Soulières, Sandrine Faivre, Ricard Mesı́a, Éva Remenár, Shau-Hsuan Li, А. А. Карпенко, Arunee Dechaphunkul, Ulrich Keilholz, Laura Kiss, Jin‐Ching Lin, Rajnish Nagarkar, László Tamás, Sung‐Bae Kim, József Erfán, Sabine Turri, Debarshi Dey, Arunava Chakravartty, Paola Aimone, Cristian Massacesi, Lisa Licitra

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicPI3K/AKT/mTOR signaling in cancer
Canadian institutionsCentre Hospitalier de l’Université de Montréal
Fundersnot available
KeywordsMedicinePaclitaxelPlaceboHead and neckInternal medicineBasal cellHead and neck squamous-cell carcinomaOncologyChemotherapyHead and neck cancerSurgeryCancerPathology

Abstract

fetched live from OpenAlex

6008 Background: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in HNSCC, contributing to treatment resistance and disease progression. Buparlisib (BUP) is a pan-PI3K inhibitor that elicits tumor control in preclinical models of HNSCC and shows signs of clinical activity in other squamous cancers. Methods: In this phase II study (NCT01852292), patients (pts) with recurrent/metastatic HNSCC progressing after platinum-based therapy were randomized (1:1) to receive BUP (100 mg/day) + paclitaxel (PAC; 80 mg/m2/week) or placebo (PBO) + PAC, stratified by prior lines of treatment (1 vs 2) and study site (North America vs rest of world), until progressive disease (PD) or discontinuation. The primary endpoint was progression-free survival (PFS; per RECIST v1.1). Overall survival (OS) was the key secondary endpoint; other secondary endpoints included overall response rate (ORR) and safety (per CTCAE v4.03). Results: As of August 31, 2015, 158 pts were randomized to receive BUP + PAC vs PBO + PAC (n = 79 each), with 10 (13%) and 7 (9%) pts ongoing, respectively. Median age was 59 vs 58 years; 29% vs 39% of pts had laryngeal/hypopharyngeal primary tumors; 67% vs 79% were human papillomavirus (HPV)-negative; and 52% vs 38% had received a prior EGFR inhibitor. Primary reasons for treatment discontinuation were PD in 46% vs 60% of pts, and adverse events (AEs) in 9% vs 14%. Median PFS was improved for BUP vs PBO (4.6 vs 3.5 months; hazard ratio [HR] 0.65 [95% CI: 0.45–0.95]). Posterior probability of (HR < 1) was > 97.5%. The PFS improvement was consistent across exploratory subgroups. ORR was 39% vs 14%. Median OS at data cut-off was 10.0 vs 6.5 months (HR 0.71 [95% CI: 0.46–1.1]), based on 84/112 (75%) planned deaths. Grade 3/4 AEs ( ≥ 10% of pts) were hyperglycemia (22% vs 3%), anemia (18% vs 12%), neutropenia (17% vs 5%), and fatigue (8% vs 10%). Conclusions: The BERIL-1 study met its primary endpoint, demonstrating improved PFS for the combination of BUP + PAC vs PAC, notably in pts with poor prognosis HNSCC (73% of pts were HPV-negative). The safety profile of the combination was manageable. Follow-up for final OS analysis is ongoing. Clinical trial information: NCT01852292.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.024

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0010.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0070.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.382
Teacher spread0.341 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicPI3K/AKT/mTOR signaling in cancerFrench-language works237,207